A phase II study of the remission induction and maintenance therapy by rituximab for rituximab naive low grade B cell lymphoma.
Phase 2
- Conditions
- low grade B cell lymphoma
- Registration Number
- JPRN-UMIN000001191
- Lead Sponsor
- Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
1.presence of central nervous invasion(clinical or pathological). 2.transformed patients (clinical or pathological). 3.past history of glaucoma. 4.past history of severe drug allergy. 5.HIV Ab positive or HTLV-1 Ab positive. 6.HBsAg positive, HBsAb positive, or HCV Ab positive. 7.severe cardiac disease 8.hepatic cirrhosis 9.uncontrollable diabetis melitus 10.patients with dialysis 11.lung fibrosis or interstitial pneumonitis 12.other active malignancies 13.pregnant or feeding female 14.severe mental disorder 15.systemic therapy with corticosteroid 16.judged for inappropriate with other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method complete response rate, 3 years over all survival, safety, 3 years progression free survival